secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001628280-21-015447
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M
--------------------------------------------------------------------------------

- Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.
- Net loss narrowed to $3.8M ($0.08/sh) from $8.3M loss; non-GAAP adjusted EBITDA $7.8M (20% margin).
- Full-year 2021 revenue guidance raised to $168-171M; adjusted EBITDA margin guided to 23%-25%.
- Record quarterly MACI biopsies and Epicel grafting; MACI biopsies up >50% in H1 2021 vs H1 2020.
- Cash and investments $116M, no debt; operating cash flow $4.8M in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/0001628280-21-015447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/vcel-20210804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-015447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer